Install
Stay informed on the latest biopharmaceutical news, trends, and developments in Asia Pacific with BioPharma APAC. BioPharma Asia ( APAC ) provides in-depth analysis, insights, and expert commentary on drug development, regulatory updates, and industry partnerships in the region.
- 60articles · 30d
- 16+ hour agolatest article
- Aug 15, 2026earliest in window
- 97%with images
- 212avg words
- Medical 45
- Health & Wellness 36
- Economy, Business & Finance 23
- Health 20
- Business & Industrial 19
- Science & Technology 17
- Science & Nature 7
- Finance & Business 6
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Nobody Is the Payer
1+ week, 1+ day ago (229+ words) 04 September 2026 | Friday | Analysis Each payer system in this story is described from its agency's own published guidance and official materials, cited in the sources note. The same question is asked of each: what in the published method could receive a…...
SIBIONICS Showcases AI-Powered GS3 Glucose Monitoring, Advances Integrated Diabetes Care at Melbourne Congress
1+ week, 6+ day ago (161+ words) 01 September 2026 | Tuesday | News SIBIONICS showcased its sensor innovation and AI-powered glucose monitoring at the joint IDF-WPR, ADC and Metabolic Diseases 2026 congress, held in Melbourne from 18–21 August. Through Booth #1, a scientific symposium and on-site interviews with Credentialled Diabetes Educators (CDEs), the…...
Ascletis Doses First Patient in Global Phase III Programme for Oral GLP-1 Obesity Drug ASC30
1+ week, 6+ day ago (270+ words) 01 September 2026 | Tuesday | News - Expected to enroll approximately 4,600 participants with obesity or overweight across two pivotal trials (AURORA-1 and AURORA-2) in the U.S., Europe, and Canada. - Global Phase III clinical program to investigate efficacy and safety of three maintenance doses (20 mg, 40 mg,…...
The Accidental Gerotherapeutic
2+ week, 1+ day ago (773+ words) 30 August 2026 | Sunday | Analysis Figure 1. Endpoint coverage map: where the incretin class has outcome evidence, and where it does not. Seventeen endpoints across three bands, scored against five evidence tiers. Everything above the dashed line is an organ disease endpoint measured…...
CureGene Doses First Subject in Australia Phase I Trial of Oral Metabolic Drug CG-0416
3+ week, 16+ hour ago (126+ words) 24 August 2026 | Monday | News CureGene recently announced that the first subject has been dosed in its Phase I clinical trial of CG-0416, a novel oral liver-targeting THR-β agonist developed in-house, in Australia. Subject enrollment is progressing smoothly. "The first subject dosed…...